Please assess the completion status of the following clinical trial:

Trial Title: Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of cadaver or non HLA identical living donor transplantation (tx), Re-tx recipient (second tx) allowed, but no organ other than a kidney (ie no prev k/p)~* Females of CBP must have neg preg test at the time of study enrollment (SOC) \& agree to practice birth control for duration of the study, or for 6 weeks after the last dose of Myfortic~Exclusion Criteria:~* Subjects who are pregnant or nursing.~* Current malignancy or a malignancy in the past 5 years, except for excised skin CA (BCC or SC)~* Multi-organ tx, ABO incompatible and + CM~* Subjects with a current PRA \>50% within the past 30 days pre tx~* Subjects with active current infection requiring continued use of antibiotics, or the presence of chronic active hepatitis B (surface antigen +) or +HCV.~* Exclude for subjects who have received an investigational drug within 4 weeks of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine

Based on this trial design, predict the completion outcome and termination type (if applicable).